Thermo Fisher Scientific, the world leader in serving science, has announced the opening of its Cryo-Electron Microscopy (cryo-EM) Drug Discovery Center (CDDC) in South San Francisco, US.
The new center provides pharmaceutical and biotechnology innovators with immersive, hands-on access to advanced cryo-EM technologies designed to accelerate structural insights and the development of life-saving therapies.
The CDDC provides direct access to advanced cryo-EM innovation and scientific expertise while significantly lowering the barriers to adoption. The use of cryo-EM not only expands the range of therapeutic targets and advanced therapies for structure-based methods but also can help pharmaceutical companies get drugs to clinics faster. Structure-guided drugs have more than twice the rate of clinical success in half the preclinical time and at half the cost, compared with industry standards.
The CDDC combines state-of-the-art cryo-EM instrumentation with a collaborative and collegial scientific environment for pharmaceutical and biotechnology innovators who are looking to expedite the path from discovery to development.
The opening of the center in the Oyster Point area of South San Francisco builds on the success of the UK Pharmaceutical Cryo-EM Consortium, established in Cambridge, United Kingdom, in 2016.
